Solid Biosciences Inc. (SLDB)
SLDB moved a median of -0.17% 30 minutes after news, and -0.77% by the close. How SLDB actually reacts to news — the realized, point-in-time move the market made, measured across 375 labeled events over the last three years with zero look-ahead.
SLDB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 374 |
| 30-min | -0.17% | 46% | 375 |
| 60-min | -0.20% | 47% | 375 |
| to close | -0.77% | 48% | 367 |
| Middle 50% of SLDB reactions | -2.48% to +1.78% |
|---|---|
| Median reaction (30-min) | -0.17% |
| Measured reactions | 375 |
Half of all Solid Biosciences Inc. news events land between -2.48% and +1.78% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How SLDB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 17 | -0.41% | 41% | -2.17% |
| Coverage initiations | 36 | -0.42% | 28% | -1.17% |
| Rating reiterations | 77 | -0.91% | 23% | -0.91% |
| Price-target cuts | 14 | -0.41% | 36% | -1.18% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how SLDB ranks against every other measured name →
That’s how SLDB usually reacts — get an email when it moves on news →Email me when SLDB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SLDB's baseline. Nothing else.
Recent SLDB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.35% | -4.06% | |
| Solid Biosciences to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +4.28% | +3.68% | |
| Form 10-Q Solid Biosciences Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.65% | -1.64% | |
| Form 8-K Solid Biosciences Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.65% | -1.64% | |
| Form S-3ASR Solid Biosciences Inc. | SEC filing · Form S-3ASR | SEC EDGAR | +0.65% | -1.64% | |
| Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +0.65% | -1.64% | |
| Form 8-K Solid Biosciences Inc. For: Jun 10 | SEC filing · Form 8-K | SEC EDGAR | -0.23% | +9.06% | |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -2.98% | -6.80% | |
| Solid Biosciences to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.82% | -1.10% | |
| Form 10-Q Solid Biosciences Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.33% | -1.60% | |
| Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates | Press release | GlobeNewswire | +1.33% | -1.60% | |
| Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy | Press release | GlobeNewswire | +0.19% | -2.08% | |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.40% | +1.40% | |
| Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy | Press release | GlobeNewswire | +1.56% | +2.98% | |
| Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy | Press release | GlobeNewswire | +1.07% | -0.53% | |
| Form ARS Solid Biosciences Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.71% | -3.42% | |
| Form DEF 14A Solid Biosciences Inc. For: Jun 10 | SEC filing · Form DEF | SEC EDGAR | -1.71% | -3.42% | |
| Form DEFA14A Solid Biosciences Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.71% | -3.42% | |
| Form 8-K Solid Biosciences Inc. For: Apr 10 | SEC filing · Form 8-K | SEC EDGAR | -1.25% | +4.74% | |
| Form PRE 14A Solid Biosciences Inc. For: Jun 10 | SEC filing · Form PRE | SEC EDGAR | -1.25% | +4.74% | |
| Solid Biosciences to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.13% | +3.06% | |
| Form EFFECT Solid Biosciences Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.51% | +1.37% | |
| Rett Syndrome Research Trust Appoints Genevieve Laforet, MD, PhD as Chief Medical Officer, Strengthening Leadership in Genetic Medicine Development | Press release | PR Web | -0.54% | -1.34% | |
| Form 10-K Solid Biosciences Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.41% | -5.00% | |
| Form S-3 Solid Biosciences Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.41% | -5.00% | |
| Form S-8 Solid Biosciences Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.41% | -5.00% | |
| Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | Press release | GlobeNewswire | -0.41% | -5.00% | |
| Form 8-K Solid Biosciences Inc. For: Mar 11 | SEC filing · Form 8-K | SEC EDGAR | -0.40% | +3.49% | |
| Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial | Press release | GlobeNewswire | — | +2.73% | |
| Form 8-K Solid Biosciences Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +14.20% | +16.23% | |
| Solid Biosciences Announces Oversubscribed $240 Million Private Placement | Press release | GlobeNewswire | +1.76% | +8.00% | |
| Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference | Press release | GlobeNewswire | +1.76% | +8.00% | |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.17% | +0.17% | |
| Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy | Press release | GlobeNewswire | -2.48% | +6.19% | |
| Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +2.66% | +1.88% | |
| Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101 | Press release | GlobeNewswire | +2.81% | +12.60% | |
| Solid Biosciences Doses First Participant in First-in-Class Phase 1b FALCON Trial Evaluating SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia | Press release | GlobeNewswire | -3.42% | -0.38% | |
| Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia | Press release | GlobeNewswire | +0.19% | -2.09% | |
| Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | +0.00% | +3.39% | |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.00% | +3.39% | |
| Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services | Press release | GlobeNewswire | +1.55% | -7.88% | |
| Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum | Press release | GlobeNewswire | -1.20% | -2.23% | |
| Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia | Press release | GlobeNewswire | -0.98% | -2.07% | |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.39% | -1.73% | |
| Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101 | Press release | GlobeNewswire | +1.42% | +2.84% | |
| Solid Biosciences to Participate at Upcoming Investor Conferences | Press release | GlobeNewswire | -0.73% | +10.22% | |
| Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy | Press release | GlobeNewswire | +0.51% | +6.98% | |
| Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -6.98% | -12.86% | |
| Form 10-Q Solid Biosciences Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -5.10% | -6.48% | |
| Form 8-K Solid Biosciences Inc. For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | -5.10% | -6.48% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SLDB section they belong to.
Where else SLDB is measured.
SLDB earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. - Class A (AMRX) | 377 | -0.08% | 46% |
| Autolus Therapeutics plc - American Depositary Shares (AUTL) | 377 | -0.00% | 45% |
| Halozyme Therapeutics, Inc. (HALO) | 374 | -0.11% | 48% |
| RITTER PHARMACEUTICALS (RTTR) | 374 | -0.61% | 37% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Solid Biosciences Inc.'s median reaction calculated?
Every labeled SLDB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 375 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of SLDB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SLDB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.